Back
Natera Inc (NTRA)
BiotechnologyNTRA · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$390.79
−1.21%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-1.52
ROE
-15.0%
Gross margin
65.1%
Debt/Equity
0.14x
Revenue growth
38.8%
Natera Inc — company intelligence
Earnings surprises
Q2 2026$-0.47 vs $-0.50 est+6.7%
Q1 2026$-0.60 vs $-0.55 est-9.7%
Q4 2025$0.36 vs $-0.52 est+169.1%
Q3 2025$-0.64 vs $-0.38 est-68.2%
Analyst consensus · 30 analysts
26 Buy4 Hold0 Sell
Updated Oct 8, 2026
Insider activity · 90 days
1 buy105 sellsnet -212,655 shares
Sheena JonathanSell 450 · Sep 16, 2026
Sheena JonathanSell 800 · Sep 16, 2026
Sheena JonathanSell 200 · Sep 16, 2026
Recent SEC filings
4 — Insider transaction reportSep 25, 2026
4 — Insider transaction reportSep 18, 2026
4 — Insider transaction reportSep 17, 2026
Latest news
RBC Capital Maintains Outperform on Natera, Raises Price Target to $460 — Benzinga · 2w ago
Tracking Philippe Laffont's Coatue Management Portfolio - Q2 2026 Update — SeekingAlpha · 2w ago
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx — Yahoo · 2w ago
Why Is Natera (NTRA) Stock Soaring Today — Yahoo · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.